Report      Database

    Global Osteoporosis Market & Drugs Analysis 2010 - 2015

    Date: 01 Sep, 2011              Type: Life Science              Pages: 72

    Global Osteoporosis Market & Drugs Analysis 2010 - 2015
    • Electronic Access - Single User License
      $950.00
    • CD-ROM Mail Delivery
      $1,050.00
    • Hard-copy Mail Delivery
      $1,050.00
    • Electronic Access - Multi User License
      $1,500.00

    Osteoporosis Market Overview
     
    Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to reach 16 Billion by 2015. This significant growth is primarily attributed to strong treatment options currently available in the market as well as strong pipeline products. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future.
     
    Fosamax was the undisputed leading product in the history of global osteoporosis drug market till 2007. It has a market share of nearly 37% in 2007 but, declined to 5% by 2015 due to patent expiry and competition from cheaper generics. Boniva and Evista were leading the osteoporosis market till 2010 but the dynamics of osteoporosis market is expected to change by 2011 as Prolia is going to be introduced in the market. It is predicted that Prolia will lead the market with nearly 45% share by 2015. 
     
    The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven by the launch of several promising pipeline drugs, including Amgen’s Prolia (denosumab), companies are looking for innovative ways to maximize revenues from their products nearing the end of their lifecycles.
     
    Report Details
     
    “Global Osteoporosis Market & Drugs Analysis 2010 – 2015” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:
     
    •  Global Osteoporosis  Market (2009 to 2015)
    •  Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market and market
       share data of (2006 to 2014) 
    •  Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva, Evista, Forteo,
        Viviant/Conbriza, Miacalcin, Prolia) sales and market share data of  2007 to 2015 
    •  Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market share data of
       (2009 to 2015)
    •  Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market data of (2005
        to 2015) 
    •  Pipeline Developmental Agents (Odanacatib, Aprela) Future Trends    
    •  Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis – Revenue in Osteoporosis
       Market (2007 to 2010), Strength & Weakness in Osteoporosis Market
     
    Research Highlights
     
    •  Global Osteoporosis drug  market is expected to reach the figure of US$ 16 Billion by 2015
    •  United States Osteoporosis drug market was nearly US$ 5 Billion in 2010 
    •  United States & China together is expected to control 61% market share in osteoporosis drug market  
        by 2015 
    •  Although SERM is increasing its market share year on year but Bisphosphonates will continue to
       dominate the osteoporosis drug class segment with 56% in 2014
    •  Prolia will lead the Osteoporosis drug market with 45% share by 2015
     
    Data Sources 
     
    Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, News websites, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases. 

    1.    Executive Summary
    2.    Global Osteoporosis Market
     
    3.    Global Osteoporosis Market Share (2007 – 2015) 

    3.1    By Drug Class - Osteoporosis Market Share & Forecast
    3.2    By Drug Market Share - Osteoporosis Market Share & Forecast
    3.3    By Country (USA, European Union, Japan, China, India, Korea) - Osteoporosis Drug Market Share & Forecast
     
    4.    By Country – Osteoporosis Market & Forecast (2008 – 2015) 
    4.1    United States Osteoporosis Market & Forecast
    4.2    European Union Osteoporosis Market & Forecast
    4.3    Japan Osteoporosis Market & Forecast
    4.4    China Osteoporosis Market & Forecast
    4.5    Korea Osteoporosis Market & Forecast
    4.6    India Osteoporosis Market & Forecast
     
    5.    Osteoporosis Drugs Classes Market & Forecast (2004 – 2014) 
    5.1    Global Bisphosphonate Market & Forecast
    5.2    Global Selective Estrogen Receptor Modulators (SERM) Market & Forecast
    5.3    Global Parathyroid Hormone (PTH) Market & Forecast
    5.4    Global Calcitonin Market & Forecast
     
    6.    Osteoporosis Drugs Market Analysis & Forecast (2004 – 2015) 
    6.1    Bisphosphonate Drugs Market & Forecast
    6.1.1    Fosamax (Alendronate) 
    6.1.2    Bonviva/Boniva (Ibandronic Acid) 
    6.1.3    Reclast/Aclasta
    6.1.4    Actonel (Risedronate) 
    6.2    SERMs Drugs Market & Forecast
    6.2.1    Evista (Raloxifene) 
    6.2.2    Viviant/ Conbriza (Bazedoxifene) 
    6.3    Parathyroid Hormone Drugs Market & Forecast
    6.3.1    Forteo
    6.4    Calcitonin Drugs Market & Forecast
    6.4.1    Miacalcin
    6.5    Prolia (Denosumab) 
     
    7.    Pipeline Drugs in Osteoporosis Market Analysis
    7.1    Odanacatib (MK 0822) 
    7.2    Aprela (Bazedoxifene) 
     
    8.    Licensing Deals in Osteoporosis Drug Market (2008 – 2009) 
     
    9.    Key Companies Analysis
    9.1    Eli Lilly
    9.1.1    Eli Lilly Revenue in Osteoporosis Segment
    9.1.2    Strength
    9.1.3    Weaknesses
    9.2    Roche
    9.2.1    Roche Revenue in Osteoporosis Segment
    9.2.2    Strength
    9.2.3    Weaknesses
    9.3    Amgen
    9.3.1    Strength
    9.3.2    Weaknesses
    9.4    Merck
    9.4.1    Merck Revenue in Osteoporosis Segment
    9.4.2    Strength
    9.4.3    Weaknesses
    9.5    Novartis
    9.5.1    Novartis Revenue in Osteoporosis Segment
    9.5.2    Strength
    9.5.3    Weaknesses

    List of Figures:
     
    Figure 2 1: Global – Osteoporosis Market (Million US$), 2009 – 2010
    Figure 2 2:  Global – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
    Figure 3 1: Global – Osteoporosis Drug Class Market Share (Percent), 2006 – 2010
    Figure 3 2: Global – Forecast for Osteoporosis Drug Class Market Share (Percent), 2011 – 2014
    Figure 3 3: Global – Osteoporosis Drug Market Share (Percent), 2007 – 2010
    Figure 3 4: Global – Forecast for Osteoporosis Drug Market Share (Percent), 2011 – 2015
    Figure 3 5: Global – Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2009 – 2010
    Figure 3 6:  Global – Forecast for Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2011 – 2015
    Figure 4 1: United States – Osteoporosis Market (Million US$), 2008 – 2010
    Figure 4 2: United States – Forecast for Osteoporosis Market (Million US$), 2011 – 2021
    Figure 4 3: European Union – Osteoporosis Market (Million US$), 2009 – 2010
    Figure 4 4: European Union – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
    Figure 4 5: Japan – Osteoporosis Market (Billion Yen), 2001 – 2010
    Figure 4 6: Japan – Forecast for Osteoporosis Market (Billion Yen), 2011 – 2015
    Figure 4 7: China – Osteoporosis Market (Million US$), 2004 – 2010
    Figure 4 8: China – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
    Figure 4 9: Korea – Osteoporosis Market (Million US$), 2001 – 2010
    Figure 4 10: Korea – Forecast for Osteoporosis Market (Million US$), 2011 – 2015
    Figure 4 11: India – Osteoporosis Market (Million INR), 2007 – 2010
    Figure 4 12: India – Forecast for Osteoporosis Market (Million INR), 2011 – 2015
    Figure 5 1: Global –  Bisphosphonate Market (Million US$), 2004 – 2010
    Figure 5 2: Global – Forecast for Bisphosphonate Market (Million US$), 2011 – 2014
    Figure 5 3: Global – SERM Market (Million US$), 2004 – 2010
    Figure 5 4: Global – Forecast for SERM Market (Million US$), 2011 – 2014
    Figure 5 5: Global – PTH Market (Million US$), 2004 – 2010
    Figure 5 6: Global – Forecast for PTH Market (Million US$), 2011 – 2014
    Figure 5 7: Global – Calcitonin Market (Billion US$), 2004 – 2010
    Figure 5 8: Global – Forecast for Calcitonin Market (Billion US$), 2004 – 2010
    Figure 6 1: Global – Fosamax Drug Sales (Million US$), 2003 – 2010
    Figure 6 2: Global – Forecast for Fosamax Drug Sales (Million US$), 2011 – 2015
    Figure 6 3: Global – Boniva Drug Sales (Million US$), 2005 – 2010
    Figure 6 4: Global – Forecast for Boniva Drug Sales (Million US$), 2011 – 2015
    Figure 6 5: Global – Reclast/Aclasta Drug Sales (Million US$), 2007 – 2010
    Figure 6 6: Global – Forecast for Reclast/Aclasta Drug Sales (Million US$), 2011 – 2015
    Figure 6 7: Global – Actonel Drug Sales (Million US$), 2004 – 2010
    Figure 6 8: Global – Forecast for Actonel Drug Sales (Million US$), 2011 – 2013
    Figure 6 10: Global – Evista Drug Sales (Million US$), 2001 – 2010
    Figure 6 11: Global – Forecast for Evista Drug Sales (Million US$), 2011 – 2015
    Figure 6 12: Global – Viviant/Conbriza Drug Sales (Million US$), 2010 – 2015
    Figure 6 13: Global – Forteo Drug Sales (Million US$), 2003 – 2010
    Figure 6 14: Global – Forecast for Forteo Drug Sales (Million US$), 2011 – 2015
    Figure 6 15: Global – Miacalcin Drug Sales (Million US$), 2004 – 2010
    Figure 6 16: Global – Forecast for Miacalcin Drug Sales (Million US$), 2011 – 2015
    Figure 6 17: Global – Forecast for Prolia Drug (Million US$), 2010 – 2016
    Figure 7 1:  Global – Forecast for Odanacatib Drug (Million US$), 2012 – 2015
    Figure 7 2: Global – Forecast for Aprela Drug Sales (Million US$), 2011 – 2015
    Figure 9 1: Eli Lilly – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
    Figure 9 2: Roche – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
    Figure 9 3: Merck – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
    Figure 9 4: Novartis – Osteoporosis Drug Revenue (Million US$), 2007 – 2010
     

    List of Tables:
     
    Table 6 1: Actonel (Eisai, P&G and Sanofi-Aventis) – Sales (Million US$), 2004 – 2013
    Table 6 2: Benet (Risedronate) – Sales (Million US$), 2004 – 2013
    Table 9 1: Osteoporosis – Drugs Cost Comparison (US$) in 1 Year


    Related Products

    • Global Spinal Fusion Market, Procedure Volume and Forecast


      Global Spinal Fusion Market, Procedure Volume and Forecast
      Spinal fusion is multi Billion dollar market with huge future potential. In 2014 Spinal fusion market was more than US$ 20 Billion. Germany, United States and China are the top three markets (not in the same chronological order) worldwide. In 2014, Spinal fusion procedure volume has crossed over 1 M...
      Date: 23 Nov, 2015
      Type: Drugs & Pharmaceuticals
      Pages: 62
      Price: $1,000.00
    • Global Osteoporosis Market, Patients, Companies & Forecast


      Global Osteoporosis Market, Patients, Companies & Forecast
      Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis patients worldwide....
      Date: 24 Sep, 2015
      Type: Life Science
      Pages: 124
      Price: $1,100.00